Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward

Highlights • The Sanofi Pasteur dengue vaccine candidate is in late-stage development. • It showed consistent safety and efficacy in ≥9 year individuals in endemic countries. • It could be an important component of integrated dengue prevention efforts. • Additional data may inform on the impact of v...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2015-12, Vol.33 (50), p.7100-7111
Hauptverfasser:	Guy, Bruno, Briand, Olivier, Lang, Jean, Saville, Melanie, Jackson, Nicholas
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Animals Antigens Clinical Trials as Topic Confidence intervals Dengue Dengue - epidemiology Dengue - prevention & control Dengue fever Dengue Vaccines - adverse effects Dengue Vaccines - immunology Dengue Vaccines - isolation & purification Drug Discovery - methods Drug Evaluation, Preclinical Drug-Related Side Effects and Adverse Reactions flavivirus Humans Immunization Schedule Manufacturing Quality control Safety Tetravalent dengue vaccine Treatment Outcome Vaccine Vaccines Vaccines, Attenuated - adverse effects Vaccines, Attenuated - immunology Vaccines, Attenuated - isolation & purification Vector-borne diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • The Sanofi Pasteur dengue vaccine candidate is in late-stage development. • It showed consistent safety and efficacy in ≥9 year individuals in endemic countries. • It could be an important component of integrated dengue prevention efforts. • Additional data may inform on the impact of vaccinating. • Pending licensure, post-marketing studies will further assess effectiveness and safety.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2015.09.108